Rixubis Seen as Safe, Effective for Hemophilia B in Real-world Study

Rixubis Seen as Safe, Effective for Hemophilia B in Real-world Study

283750

Rixubis Seen as Safe, Effective for Hemophilia B in Real-world Study

Rixubis safely and effectively prevents and manages bleeding in children and adults with hemophilia B, a real-world study from South Korea reports. The study, “Safety and effectiveness of Rixubis in patients with hemophilia B: a real-world, prospective, postmarketing surveillance study in South Korea,” was published in the journal Blood Research. Hemophilia B is caused by missing or defective factor IX (FIX), an essential blood clotting protein. Rixubis, marketed by Takeda, was the first engineered FIX product to…

You must be logged in to read/download the full post.